PICO Advisory Sub-Committee - Applications Considered
1449 - Genetic testing for Alport syndrome
1452 - Pembrolizumab (MK-3475) in Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma
1453 - PD-L1 testing for access to pembrolizumab in patients with unresectable mesothelioma
1454 - Diagnostic testing for ROS proto-oncogene 1 (ROS1) rearrangements in non-small cell lung cancer (NSCLC) to determine eligibility for crizotinib treatment
1457 - PD-L1 (Programmed Death 1 Ligand) IHC (immunohistochemistry) testing for access to pembrolizumab as first-line therapy for patients with unresectable or metastatic bladder cancer ineligible for cisplatin-based therapy
1458 - Non-Invasive Prenatal Testing (NIPT)
1460 - Blue-light cystoscopy with hexaminolevulinate as an adjunct to standard white light cystoscopy, for the diagnosis, treatment and management of non-muscle invasive bladder cancer (NMIBC)
1461 - Non-invasive prenatal testing for common trisomies (21, 18 and 13)